› Forums › General Melanoma Community › PD-1 Question
- This topic has 6 replies, 2 voices, and was last updated 12 years, 1 month ago by
Mat.
- Post
-
- January 8, 2014 at 5:45 pm
Can anyone speak to the topic of "compassionate use", perhaps using ipi as an example? In other words, how does it work? How is announced? Is there still exclusionary criteria? Is it confined to certain trial sites? I'm not looking for predictions on when compassionate use for PD-1 will be available–rather I'm looking for info on what compassionate use might look like if and when it becomes available. Thanks.
- Replies
-
-
- January 9, 2014 at 2:31 pm
I doubt it would ever be "announced". It is usually on a case by case basis and often a trial doctor would often be the one to ask for an "exception" for a specific patient. I'm sure patients could also specifically petition the company. Not sure how much success that would have. It often comes down to how much product the company has, how easy/difficult to manufacture more and how much is needed for current or future clinical trials. If product is scarce or manufacturing practices difficult, then compassionate use is unlikely. The company will want to keep all its resources for gaining FDA approval first – then anyone could get the product.
-
- January 9, 2014 at 2:31 pm
I doubt it would ever be "announced". It is usually on a case by case basis and often a trial doctor would often be the one to ask for an "exception" for a specific patient. I'm sure patients could also specifically petition the company. Not sure how much success that would have. It often comes down to how much product the company has, how easy/difficult to manufacture more and how much is needed for current or future clinical trials. If product is scarce or manufacturing practices difficult, then compassionate use is unlikely. The company will want to keep all its resources for gaining FDA approval first – then anyone could get the product.
-
- January 9, 2014 at 2:31 pm
I doubt it would ever be "announced". It is usually on a case by case basis and often a trial doctor would often be the one to ask for an "exception" for a specific patient. I'm sure patients could also specifically petition the company. Not sure how much success that would have. It often comes down to how much product the company has, how easy/difficult to manufacture more and how much is needed for current or future clinical trials. If product is scarce or manufacturing practices difficult, then compassionate use is unlikely. The company will want to keep all its resources for gaining FDA approval first – then anyone could get the product.
-
- You must be logged in to reply to this topic.